Gossamer Bio Inc. Common Stock (GOSS)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I have spent my life looking for understandable businesses with durable competitive advantages, honest accounting, and a margin of safety. Gossamer Bio does not fit that mold. It is a clinical-stage biotech with 161 employees, pinning its future on seralutinib for pulmonary arterial hypertension. There is no commercial product yet, so there is no moat in the ordinary sense—only intellectual property, trial data, and regulatory risk. The financials are those of a cash-consuming research operation. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported $9.2 million of revenue and $16.9 million of net income, but that single quarter does not erase the pattern: fiscal Q1 2026 lost $46.7 million; fiscal Q3 2025 lost $48.2 million; fiscal Q2 2025 lost $38.3 million. For FY2025, revenue was $48.5 million and net loss $170.4 million, or -$0.75 per diluted share, versus FY2024 revenue $114.7 million and net loss $56.5 million. Trailing free cash flow is negative $162.6 million, a FCF yield of -3.4% on the $4.8 billion market cap. The FairStock metrics confirm fragility: Piotroski 3/9, Altman Z-score -12.01, ROCE -62.39%, P/E -0.18, P/B N/A, and a FairStock score of 21/100. At the 2026-10-13 close of $9.76, the market values hope at $4.8 billion. The 52-week range of $0.11 to $14.72 shows how violently sentiment swings. Without profits, book value, or predictable cash flows, I cannot calculate intrinsic value with any confidence. This is speculation on clinical outcomes, not a Graham-style bargain.

In plain English: Gossamer Bio is a small healthcare company trying to develop a drug for a serious lung condition. It does not yet sell a regular product, has mostly lost money, and its latest numbers show heavy spending. At $9.76, the stock price looks expensive compared with its current sales and losses, so much of the value depends on whether the drug succeeds.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer